ClinicalTrials.Veeva

Menu

Premature Coronary Artery Disease and Familial Dyslipidemia in Patients Presenting With Acute Coronary Syndrome

Cairo University (CU) logo

Cairo University (CU)

Status

Completed

Conditions

Coronary Artery Disease
Premature
Familial Dyslipidemia
Acute Coronary Syndrome

Treatments

Other: Cardiovascular risk assessment

Study type

Observational

Funder types

Other

Identifiers

NCT07267312
AFHSRMREC/2023/CARDIOLOGY/678

Details and patient eligibility

About

This study aimed to explore the relationship between familial hypercholesterolemia and premature coronary artery disease, particularly in the context of acute coronary syndrome, by reviewing current evidence and highlighting the need for improved screening and aggressive lipid-lowering strategies in high-risk populations.

Full description

Dyslipidaemia and familial hypercholesterolemia (FH) are a common disorder that causes premature coronary artery disease.

The lifelong burden of elevated low-density lipoprotein cholesterol (LDL-C) in FH accelerates endothelial dysfunction and plaque formation, often culminating in acute coronary syndrome (ACS) at a young age. ACS in patients with undiagnosed FH may be their first clinical manifestation, underscoring the importance of early identification and intervention.

Enrollment

2,000 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥18 years at the time of presentation.
  • Both sexes.
  • Confirmed diagnosis of coronary artery disease (CAD), established by clinical presentation, electrocardiographic findings, elevated cardiac biomarkers, and/or angiographic evidence of ≥50% luminal stenosis in at least one major coronary artery.
  • Hospital admission to the participating cardiology department between [insert study period, e.g., January 2020 and December 2024] for acute coronary syndrome (ACS), including unstable angina, non-ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI).
  • Availability of complete clinical, laboratory, and echocardiographic data necessary for classification and analysis.

Exclusion criteria

  • Incomplete medical records or missing essential laboratory, imaging, or demographic data.
  • Secondary causes of dyslipidemia, including uncontrolled hypothyroidism, nephrotic syndrome, chronic liver disease, or use of lipid-altering medications (other than statins) before presentation.
  • Previous congenital or structural heart disease, cardiomyopathy, or significant valvular heart disease unrelated to CAD.
  • Severe chronic kidney disease (estimated glomerular filtration rate <30 mL/min/1.73 m²) or patients on dialysis.
  • Autoimmune, inflammatory, or systemic diseases known to influence vascular inflammation or lipid metabolism.
  • Malignancy or life expectancy <6 months due to non-cardiac causes.
  • Pregnant or lactating women.
  • Non-Saudi patients (focusing on Saudi population in southern region).

Trial design

2,000 participants in 2 patient groups

Non-premature coronary artery disease
Description:
Males aged \<55 years and females aged \<65 years.
Treatment:
Other: Cardiovascular risk assessment
Premature coronary artery disease
Description:
Males aged ≥55 years and females aged ≥65 years.
Treatment:
Other: Cardiovascular risk assessment

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems